Alpha 2.0
Login Register
» Authors » Hadjer Nacer-Laidi

Hadjer Nacer-Laidi

Explore the profile of Hadjer Nacer-Laidi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 63
Followers 0
Related Specialties
Public Health
Geriatrics
Infectious Diseases
Top 10 Co-Authors
Andrew Hayward
Verity Baynton
Paul Moss
Maria Krutikov
Aidan Irwin-Singer
Tom Palmer
Borscha Azmi
Gokhan Tut
Andrew Copas
Laura Shallcross
Published In
Lancet Healthy Longev
J Infect Dis
Open Forum Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI)
Stirrup O, Shrotri M, Adams N, Krutikov M, Nacer-Laidi H, Azmi B, et al.
Open Forum Infect Dis . 2023 Jan; 10(1):ofac694. PMID: 36713473
Background: Successive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have caused severe disease in long-term care facility (LTCF) residents. Primary vaccination provides strong short-term protection, but data are limited...
2.
Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study
Shrotri M, Krutikov M, Nacer-Laidi H, Azmi B, Palmer T, Giddings R, et al.
Lancet Healthy Longev . 2022 Jul; 3(7):e470-e480. PMID: 35813279
Background: Residents and staff in long-term care facilities have been prioritised for vaccination against SARS-CoV-2, but data on potential waning of vaccine effectiveness and the effect of booster doses in...
3.
Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study
Krutikov M, Stirrup O, Nacer-Laidi H, Azmi B, Fuller C, Tut G, et al.
Lancet Healthy Longev . 2022 May; 3(5):e347-e355. PMID: 35531432
Background: The SARS-CoV-2 omicron variant (B.1.1.529) is highly transmissible, but disease severity appears to be reduced compared with previous variants such as alpha and delta. We investigated the risk of...
4.
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI)
Stirrup O, Krutikov M, Tut G, Palmer T, Bone D, Bruton R, et al.
J Infect Dis . 2022 Apr; 226(11):1877-1881. PMID: 35429382
General population studies have shown strong humoral response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated...